These results highlight that the genetically, metabolically and clinically heterogeneity of AML should be considered and might justify the general modest growth‐inhibitory effects in preclinical AML models and clinical trials of mTOR inhibition.25, 55 Furthermore, the results highlight the relevance that comparative studies implying AML cell lines have on the determination of the anti‐leukaemia efficacy, particularly, of the effectiveness of combinatory therapy with conventional and new targeted agents. The gene discussed is MTOR; the disease is leukemia.